Table 1 Baseline characteristics
T2DM (n = 56) | Non T2DM (n = 114) | All(n = 170) | p-value | |
|---|---|---|---|---|
Age,median (range) | 66 (49–81) | 63 (37–87) | 64 (37–87) | 0.094 |
Gender,n (%) | ||||
Male | 51 (91.1%) | 97 (85.1%) | 148 (87%) | |
Female | 5 (8.9%) | 17 (14.9%) | 22 (13%) | 0.337 |
Smoking history, n (%) | ||||
Current | 27 (48.2%) | 57 (50%) | 84 (49.4%) | |
Former | 24 (42.8%) | 51 (44.7%) | 75 (44.1%) | |
Never | 3 (5.4%) | 4 (3.5%) | 7 (4.1%) | |
Unknown | 2 (3.6%) | 2 (1.8%) | 4 (2.4%) | 0.837 |
ECOG PS, n (%) | ||||
PS 0–1 | 53 (94.6%) | 102 (90.3%) | 155 (91.1%) | |
PS 2 | 3 (5.4%) | 12 (9.7%) | 15 (8.9%) | 0.331 |
Histology n (%) | ||||
Adenocarcinoma | 9 (16%) | 48 (42.1%) | 57 (33.5%) | |
Squamous | 29 (51.8%) | 43 (37.7%) | 72 (42.3%) | |
NOS | 18 (32.2%) | 23 (20.2%) | 41 (24.2%) | 0.003 |
Stage, n (%) | ||||
IIIA | 31 (55.3%) | 54 (47.4%) | 85 (50%) | |
IIIB | 23 (41.1%) | 58 (50.9%) | 81 (47.6%) | 0.321 |
Mean baseline glycemia (mmol/L) | 9.22 ± 6.35 | 5.6 ± 1.2 | 6.75 ± 4.70 | < 0.001 |
Comorbidities | ||||
Any | 34 (60.7%) | 69 (60.5%) | 103 (60.6%) | 0.981 |
Renal Insufficiency | 5 (8.9%) | 7 (6.1%) | 12 (7.1%) | 0.445 |
COPD | 21 (37.5%) | 50 (44%) | 71 (41.8%) | 0.604 |
Cardiovascular Hepatopathy | 18 (32.1%) 2 (3.6%) | 16 (14%) 0 (0%) | 34 (20%) 2 (1.2%) | 0.003 1.000 |
Platinum doublet, n (%) | ||||
Cisplatin | 27 (48.2%) | 77 (67.5%) | 104 (61.2%) | |
Carboplatin | 29 (51.7%) | 37 (32.5%) | 66 (38.8%) | 0.019 |
Total dose of RDT between 60-70Gys | 54 (96.4%) | 106 (93%) | 160 (94%) | 0.716 |